News

Bonumose Announces Key Advisory and Leadership Appointments

Bonumose, Inc. – an enzyme technology company with solutions for sugar reduction and other globally critical industries – is pleased to announce the following appointments.

  • Dr. Andrew Fordyce has accepted a key advisory role with Bonumose. Dr. Fordyce most recently was Executive Vice President and Food & Beverage Divisional Head for Novozymes, a global leader in biological solutions. His experience includes executive management in both functional and business unit organizational structures and he has had a multifaceted career that has covered biotech innovation and business strategy, marketing and business portfolio management, and process engineering and application research. Over Dr. Fordyce’s 27-year career at Novozymes he served multiple management roles including 7 years on the Novozymes’ Executive Leadership Team. Dr. Fordyce is advising Bonumose on multiple aspects of the enzyme value chain, as well as general R&D and business matters.
  • Dr. Katie Whalen. Bonumose has appointed Dr. Whalen, Director of Innovation Delivery, to the additional role of Chief of Staff. Dr. Whalen has a PhD in Biochemistry and prior to Bonumose spent 5 years at Kalsec. In her expanded role, Dr. Whalen is Bonumose’s lead on identifying and filling gaps for organizational capacity development, and also is responsible for ensuring Bonumose maintains a positive culture while scaling its production, global sales, and new product development.
  • Robert Coward. Mr. Coward recently joined Bonumose as Vice President for Finance & Accounting. Mr. Coward was with Xerox (NASDAQ: XRX), an S&P 400 company, for 28 years. Throughout his career Mr. Coward has held increasingly senior leadership roles in finance as well as operations.
  • Ross Bartels. Mr. Bartels, a recent graduate of the University of Virginia School of Law, joined Bonumose as its first in-house legal counsel. Mr. Bartels areas of focus for Bonumose include intellectual property protection, regulatory and administrative law, and general legal matters. Bonumose has over 50 granted patents globally and many more patent applications pending, and also is engaging with food ingredient regulatory bodies globally.

Bonumose is based in Albemarle County, Virginia, and was selected as a Technology Pioneer by the World Economic Forum.

Recent News

06/23/2026

Scout Space raises Series A second close from VTC Ventures, Long Knife, and 100KM

Scout Space, a space domain awareness sensor and software provider, has announced the second close of its Series A financing, adding VTC Ventures, Long Knife and 100KM to its investor syndicate. The initial close occurred in May 2026, led by Washington Harbour Partners. The funding will accelerate deployment of Scout’s in-orbit sensor network, support upcoming

06/22/2026

Icarus Medical Secures $7.2 Million Series A to Accelerate Growth and Innovation

Icarus Medical, a Charlottesville-based med-tech company focused on advancing orthopedic bracing technology, today announced the successful close of its Series A financing round. Originally targeting $5 million, the round closed oversubscribed at $7.2 million, reflecting strong investor confidence in the company’s technology platform, market momentum, and long-term vision. Orthopedic bracing company Icarus Medical closes oversubscribed

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.